Galectin Therapeutics Inc
GALT - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$218.64M
Close$
$-1.82
154.2% downside
Current Fair Value
154.2% downsideOvervalued by 154.2% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $218.64 Million |
|---|---|
| Enterprise Value | $343.14 Million |
| Earnings per Share | $-0.48 |
| Beta | 0.38 |
| Outstanding Shares | 65,875,000 |
Return
| Return on Equity | 20.35% |
|---|---|
| Return on Assets | -187.80% |
| Return on Invested Capital | -13.98% |
Valuation & Multiples
| P/E Ratio | -7.78 |
|---|---|
| PEG | -36.73 |
| Price to Sales | - |
| Price to Book Ratio | -1.12 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 17.95 |
| Enterprise Value to Net Income | -13 |
| Total Debt to Enterprise | 0.4 |
| Debt to Equity | -1.01 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
$-0.09
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
November 13, 2026
EPS Estimate
$-0.05
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 19.96% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.49%▼ 23.45% |
|---|---|
| Total Invested | $1.26M▼ 98.27% |
| Investors Holding | 7▼ 100.00% |
About Galectin Therapeutics Inc
CEO: Harold Shlevin
